CDA | Evidence Driven
CDA | Evidence Driven

Dapagliflozin

Details

Files
Generic Name:
Dapagliflozin
Project Status:
Complete
Therapeutic Area:
Diabetes mellitus, type 2
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Forxiga
Project Line:
Reimbursement Review
Project Number:
SR0428-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Submission Type:
Initial
Indications:
Diabetes mellitus (Type 2)
Recommendation Type:
List with clinical criteria and/or conditions
Final Recommendation:

Files

Recommendation and Reasons: Updated View PDF
Submission Status Report View PDF
Recommendation and Reasons: Original View PDF
Clinical Report View PDF
Pharmacoeconomic Report View PDF
Patient Group Input Submissions View PDF
Last Updated : March 22, 2024